166 related articles for article (PubMed ID: 9711219)
21. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
22. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
23. Enterococci and vancomycin resistance.
French GL
Clin Infect Dis; 1998 Aug; 27 Suppl 1():S75-83. PubMed ID: 9710674
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of action of oritavancin and related glycopeptide antibiotics.
Allen NE; Nicas TI
FEMS Microbiol Rev; 2003 Jan; 26(5):511-32. PubMed ID: 12586393
[TBL] [Abstract][Full Text] [Related]
25. Virulence profiles of vancomycin-resistant enterococci isolated from surface and ground water utilized by humans in the North West Province, South Africa: a public health perspective.
Matlou DP; Bissong MEA; Tchatchouang CK; Adem MR; Foka FET; Kumar A; Ateba CN
Environ Sci Pollut Res Int; 2019 May; 26(15):15105-15114. PubMed ID: 30924038
[TBL] [Abstract][Full Text] [Related]
26. The specter of glycopeptide resistance: current trends and future considerations.
Moellering RC
Am J Med; 1998 May; 104(5A):3S-6S. PubMed ID: 9684651
[TBL] [Abstract][Full Text] [Related]
27. Occurrence of vancomycin-resistant enterococci in relation to the administration of glycopeptide antibiotics.
Kolár M; Vágnerová I; Látal T; Kohnová I
Acta Univ Palacki Olomuc Fac Med; 1999; 142():69-71. PubMed ID: 10743728
[TBL] [Abstract][Full Text] [Related]
28. Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies.
Allen NE; LeTourneau DL; Hobbs JN; Thompson RC
Antimicrob Agents Chemother; 2002 Aug; 46(8):2344-8. PubMed ID: 12121903
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and antibacterial activity of N4-mono alkyl derivatives of novel glycopeptide LYV07ww01.
Shao C; Zhou W; Zhang S; Wei W; Ruan L; Jin Y; Sun X; Huang Y
Bioorg Med Chem Lett; 2011 Nov; 21(22):6732-8. PubMed ID: 21978682
[TBL] [Abstract][Full Text] [Related]
30. Reengineering Antibiotics to Combat Bacterial Resistance: Click Chemistry [1,2,3]-Triazole Vancomycin Dimers with Potent Activity against MRSA and VRE.
Silverman SM; Moses JE; Sharpless KB
Chemistry; 2017 Jan; 23(1):79-83. PubMed ID: 27747932
[TBL] [Abstract][Full Text] [Related]
31. Resistance of enterococci to ampicillin and glycopeptide antibiotics in Italy. The Italian Surveillance Group for Antimicrobial Resistance.
Fontana R; Ligozzi M; Mazzariol A; Veneri G; Cornaglia G
Clin Infect Dis; 1998 Aug; 27 Suppl 1():S84-6. PubMed ID: 9710675
[TBL] [Abstract][Full Text] [Related]
32. Multivalent antibiotics via metal complexes: potent divalent vancomycins against vancomycin-resistant enterococci.
Xing B; Yu CW; Ho PL; Chow KH; Cheung T; Gu H; Cai Z; Xu B
J Med Chem; 2003 Nov; 46(23):4904-9. PubMed ID: 14584941
[TBL] [Abstract][Full Text] [Related]
33. Balhimycin, a new glycopeptide antibiotic produced by Amycolatopsis sp. Y-86,21022. Taxonomy, production, isolation and biological activity.
Nadkarni SR; Patel MV; Chatterjee S; Vijayakumar EK; Desikan KR; Blumbach J; Ganguli BN; Limbert M
J Antibiot (Tokyo); 1994 Mar; 47(3):334-41. PubMed ID: 8175486
[TBL] [Abstract][Full Text] [Related]
34. Structure diversification of vancomycin through peptide-catalyzed, site-selective lipidation: a catalysis-based approach to combat glycopeptide-resistant pathogens.
Yoganathan S; Miller SJ
J Med Chem; 2015 Mar; 58(5):2367-77. PubMed ID: 25671771
[TBL] [Abstract][Full Text] [Related]
35. Vancomycin-resistant enterococci isolates from the rumen content of deer.
Lauková A
Microbios; 1999; 97(387):95-101. PubMed ID: 10453484
[TBL] [Abstract][Full Text] [Related]
36. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
Itokazu GS; Nathan C; Hariharan R; Kostman JR; Kabins SA; Weinstein RA
Chemotherapy; 1996; 42(4):235-9. PubMed ID: 8804789
[TBL] [Abstract][Full Text] [Related]
37. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala.
Ge M; Chen Z; Onishi HR; Kohler J; Silver LL; Kerns R; Fukuzawa S; Thompson C; Kahne D
Science; 1999 Apr; 284(5413):507-11. PubMed ID: 10205063
[TBL] [Abstract][Full Text] [Related]
38. Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
Printsevskaya SS; Pavlov AY; Olsufyeva EN; Mirchink EP; Preobrazhenskaya MN
J Med Chem; 2003 Mar; 46(7):1204-9. PubMed ID: 12646030
[TBL] [Abstract][Full Text] [Related]
39. Accuracy of the VITEK 2 system to detect glycopeptide resistance in enterococci.
van Den Braak N; Goessens W; van Belkum A; Verbrugh HA; Endtz HP
J Clin Microbiol; 2001 Jan; 39(1):351-3. PubMed ID: 11136798
[TBL] [Abstract][Full Text] [Related]
40. An efficient and practical method for solid-phase synthesis of tripeptide-bearing glycopeptide antibiotics: combinatorial parallel synthesis of carboxamide derivatives of chloroorienticin B.
Yasukata T; Shindo H; Yoshida O; Sumino Y; Munekage T; Narukawa Y; Nishitani Y
Bioorg Med Chem Lett; 2002 Nov; 12(21):3033-6. PubMed ID: 12372495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
